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The development of targeted therapies for KRAS, EGFR
and HER2 may increase the range of response in
patients with colorectal cancer. Mutation at codons 12
and 13 of the KRAS gene has been shown to be predic-
tive of cetuximab response in colorectal cancer. How-
ever, due to the combined effects of multiple oncogenes
involved in disease progression of patients with colorec-
tal cancer, it seems to be important to identify the
molecular factors that characterize therapy-resistance
phenotype of tumors.
Forty six paraffin-embedded colorectal cancer speci-
mens were analyzed for KRAS mutation and HER2
overexpression/amplification. A high–resolution melting
(HRM) assay and single-nucleotide polymorphisms
(SNPs) were used to detect somatic mutation in exon 2
notably condons 12 and 13 of the KRAS gene. HER2
overexpression was detected using monoclonal antibody
and confirmed by fluorescence in situ hybridization
(FISH) analysis.
KRAS mutations for codons 12 and 13 were identified
in 16/46 (34.7%) of patients by SNP. The alterations in
KRAS gene were observed in similar percentage of both
codons. Colorectal cancer showed mainly heterozygous
35G>A and 38G>A KRAS gene mutations.
HRM analysis showed presence of KRAS exon 2
mutation in 13/46 (28.2%) colorectal cancers. Despite
positive SPN results in three cases , HRM technique did
not reveal KRAS gene alteration. The concordance rate
between the two methodologies was high at 87.5%.
KRAS mutation was more frequently observed in poorly
differentiated tumors and adenocarcinomas than in
other histological types.
HER2 overexpression was found in 37/46 (80.3%) of all
colorectal cancers and in 62.1%, 61.5% of KRAS
mutation-positive cases detected by SNP and HRM tech-
niques respectively. HER2 overexpression was accompa-
nied by amplification of HER2 gene. The subgroup of
colorectal cancers with KRAS mutation and HER2 over-
expression/amplification was poorly differentiated.
In summary, the presence of HER2 overexpression/
amplification in KRAS mutation–positive colorectal can-
cers suggests a possible role for the use of specific tyrosine
kinase inhibitors in the treatment of disease.
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